As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use whole genome sequencing at a Kids First-supported sequencing center to elucidate the genetic contribution to childhood cancers, and to investigate the genetic etiology of structural birth defects.  These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Johns Hopkins is setting its sights on an end to cancer with its new Bloomberg-Kimmel Institute for Cancer Immunotherapy.

When someone with a high fever walks into a rural African clinic, diagnosis could be murky. The symptoms could be those of dengue, Ebola, West Nile disease, malaria or flu, and blood work results from distant labs, if available, often takes days. Now a handful of researchers are separately working on inexpensive, paper-based diagnostic tests that accurately pinpoint the cause of a disease in minutes and could speed up treatment and prevent its spread. The lack of funds and commercial partners however, means most might languish in labs.

Johns Hopkins is launching an immunotherapy center for cancer research with a $125 million gift from longtime Hopkins donors Michael R. Bloomberg and Sidney Kimmel, along with other donors.

GlaxoSmithKline Pharmaceuticals Ltd is looking at launching two or three combination vaccines in India in the near future, to address a host of paediatric disease. The company is also organising programmes to spread awareness about the need of vaccination among public.

Gaithersburg cell modification technology firm MaxCyte Inc. is expected to go public on the London Stock Exchange Tuesday morning.

MaxCyte, which will trade under the ticker symbol MXCT, is seeking to raise between $14 million and $15 million, said CEO and President Doug Doerfler.

The cybersecurity industry is predicted to double by 2020 and the DC metro area is the center of cybersecurity innovation in the US. Therefore it should be no surprise that the premiere accelerator for information security startups and entrepreneurs calls this area home. The accelerator is Mach37 and they’ve just announced their most recent cohort.

Physician entrepreneurs or wannapreneurs ask a lot of questions about the processes of biomedical and clinical innovation and entrepreneurship. Given their lack of training in medical school, it comes as no surprise and most have to get the information on their own.  Maybe these answers to your FAQs will help:

There is an element of synchronicity associated with blogging at this time on my work and career path at the U.S. Department of Commerce Economic Development Administration (EDA). On March 28th, I will celebrate 28 years with the Philadelphia Regional Office of EDA so in some ways, I AM living history here at DOC, part of the EDA institutional knowledge base. EDA is celebrating its 50th anniversary in 2016 and I am proud to carry the torch cheerleading for and at EDA, a DOC program that has invested and leveraged billions of dollars in its role as the only federal agency focused exclusively on economic development.

Are you a local engineering firm, technology-based company, or biohealth startup? Are you a STEM-based business in the Tri-State area? The Federal Laboratory Consortium is coming to Hagerstown on April 12, 2016 to share the latest technologies and research capabilities of the federal labs. NIST, NSA, NASA, NIH, & USDA will all be at Hagerstown Community College for the Small Business Forum from 9 a.m. to 3:30 p.m. Connect with representatives from each lab and discover how you can benefit from working with their lab.

Maryland universities have ramped up efforts in recent years to help students and faculty turn their discoveries into growing businesses but lag far behind many colleges around the country in spinning off companies and pulling in millions of dollars in licensing revenue.

SPIRIT OF INNOVATION: “We spend a lot of effort in recruitment to find the right culture fit,” says Gorkem Sevinc, CTO of emocha Mobile Health. What’s more, the solutions developed by Sevinc and his team help patients with medication and care plan adherence, a task that can literally save lives. “This drives our team to go above and beyond,” he says.

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that additional data supporting the Company’s novel, investigational anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of triple negative breast cancer, were presented at the 14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016), held in Washington, DC March 21- 23, 2016.

Our mission: improve newborn survival and health in the developing world

We are developing cutting edge healthcare technologies for where they’re gravely needed and will have an incredible impact—vulnerable populations in low-resource countries. Annually, over 46 million newborns in developing countries around the world need interventions for complications that happen at or around birth, 600,000 in Uganda alone. Every Neopenda device has the potential to save the life of a newborn for less than $1, once it is produced at scale.

For the last several years, Martine Rothblatt has been positioning United Therapeutics to manufacture transplantable human organs. This week, the founder and CEO of the Maryland biotech cornerstone told the state's tech community to get ready for a new industry to sprout from the idea.

A Baltimore health startup is among the new class of companies entering Dreamit’s accelerator program.

Timonium-based Kermit was developed by a team that consulted for hospitals on the purchase of implantable medical devices for knees, hips and other body parts.

Join us on March 30th for an evening of networking around innovation and commercialization at the BioBuzz @ Relevant Health. Meet with the organizations fueling commercialization in Maryland - BHI & TEDCO - and mingle with the first cohort of companies in the regions newest BioHealth accelerator - Relevant Health.

DATE: Wednesday, April 13, 2016 (FINAL EVENT) TIME: 3:30-5:00PM

LOCATION: Montgomery County Department of Economic Development, 111 Rockville Pike, Suite 800, Rockville, MD 20850  

We would like to offer one of our best and brightest as our final speaker for the Tech Transfer Speakers Series.  Launching one successful company is challenging, but founding six or more is an art.  Plan to attend our final program on April 13 with one of our area's prolific entrepreneurs.  Specific points of interest and discussion will include:  fundraising, launching the idea, identifying a technology that will sell, working with tech transfer officers to license the technology, and the future of innovation investment in the United States, Asia and Europe.  Bring your best questions.  This will be an exciting conversation! 

The Maryland Technology Development Corporation (TEDCO) announced today that 17 companies have received over $1.7 million in funding from the organization’s Technology Commercialization Fund (TCF) and Cyber Security Investment Fund (CIF)in the last six months. The funding will be used to advance the companies’ technology and product commercialization efforts.

Roche Holding AG, the world’s largest producer of cancer drugs, is opening the door to more external partnerships as its latest and most promising tumor-fighting treatment heads for approval this year.

The Montgomery County Economic Development Corporation (MCEDC) was officially designated as the County’s Economic Development Organization by the County Council, marking a big and bold step toward achieving greater economic competitiveness and prosperity in Montgomery County. As the County’s new lead economic development organization, MCEDC is replacing both the County Department of Economic Development (DED) and the Montgomery Business Development Corporation (MBDC) effective July 1, 2016, as the primary point of contact for the local, regional, national and international business community.

An investment firm targeting seed stage investment in health IT and other software startups is raising a $50 million fund, according to a report by Fortune.

Two of the investors behind Refactor Capital’s fund have worked for Google:  David Lee, who also co-founded SV Angel and Zal Bilimoria, who has worked for Andreessen Horowitz.

The Division of Industrial Innovation and Partnerships (IIP), within the Directorate for Engineering at the National Science Foundation, announces a nationwide search to fill multiple Program Director positions for the Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) program.

Formal consideration of interested applications will continue until these positions are filled.

Intralytix, Inc., announced today that the company has received a SBIR Phase II grant from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA), to develop a bacteriophage (or phage) cocktail effective against the larval shellfish pathogens Vibrio tubiashii and Vibrio coralliilyticus. This research will be a continuation of collaborative efforts between Intralytix and Dr. Gary Richards, the Lead Scientist at the USDA, Agricultural Research Service (ARS) laboratory in Dover, Delaware, where these phages were originally isolated and characterized. A spokesperson for the company noted that, in developing this proposed technology, Intralytix will be working closely with Dr. Chris Langdon at the Hatfield Marine Station, Oregon State University, in Newport, Oregon, and Dr. Claudia Hӓse at the College of Veterinary Medicine, Oregon State University, in Corvallis, Oregon. In addition, the company will receive continuing research support from Dr. Richards' group at the ARS USDA.

Attempting to free people with diabetes from frequent finger-pricks and drug injections, researchers have created an electronic skin patch that senses excess glucose in sweat and automatically administers drugs by heating up microneedles that penetrate the skin.

The White House on Friday appointed an executive director of its Cancer Moonshot Task Force: Gregory C. Simon, a leukemia survivor with experience in government, nonprofits, and the corporate world.

Entrepreneur Vivek Garipalli has a dim view of the way health insurance companies treat providers and patients. Patients develop trust with doctors and hospitals, and he thought insurers should be the “glue” between them instead of creating friction.

Medical device company Senseonics Holdings Inc. raised about $45 million last week in the first Greater Washington IPO of the year.

Senseonics (NYSE: SENS) originally planned to raise about $60 million by offering 18.2 million shares at a range of $3.10 to $3.50, but ultimately lowered the proposed deal size for the IPO.

While most agencies try to imitate advances in the private sector, the Department of Health and Human Services instead is emulating the process that fuels many recent innovations: startup accelerators.

Venture capitalists had a big year in Maryland in 2015.

In the fourth quarter of last year, they invested more than $451 million in 14 different Maryland companies — the largest quarter ever in the state since 2006.

Microscopic robots, powered by bacterial flagellation, are a curious branch of robotics research, potentially leading to devices that can deliver drugs, perform surgical tasks, and help out with diagnostics. While bacteria has been harnessed in the past to power small devices, having those devices actually navigate to a desired target has been a challenge. At Drexel University researchers are now using electric fields to help their bacterial biobots detect obstacles and float around them on their way to the final destination.

Looks like ARCH Venture Partners is gearing up for its ninth fund, with aims to raise $400 million, according to a regulatory filing. The Chicago-based early stage venture firm has a deep history in tech and life sciences investments – with some notable recent plays like Illumina offshoot Grail, Harvard 3D printing spinout Voxel 8, and Doug Williams’ brainchild Codiak Biosciences.

GlaxoSmithKline (GSK) and Miltenyi Biotech said they will partner to develop new cell and gene therapies through a collaboration whose value was not disclosed.

The collaboration is designed to combine GSK’s expertise in developing cell- and gene therapy–based treatments with Miltenyi Biotec’s global leadership in cell processing and related technologies in cell therapy, the companies said.

The biotech investment climate sank into deep insecurity by the close of 2015, as shown in EP Vantage‘s new “Pharma & Biotech 2015 in Review” report. The  flutterings around companies raising capital, via venture capital or IPO, diminished – which invites a retrospective on the investment environment in years past. Perhaps this will help inform how cash-hungry companies will fare this year.